Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2013

View Archived Issues

RespiVert presents results for the novel PI3K-gamma/delta inhibitor

Researchers identify novel plasma miRNA biomarkers for the diagnosis and prognosis of AAAs

Pfizer designs approach to develop potent brain-specific PET tracers

Novel RNAi therapeutics presented by Gradalis

Calimmune presents preclinical results for its anti-HIV lentiviral vector gene therapy

Targacept reports commencement of phase IIb TC-5214 study

Atopix receives U.K. Biomedical Catalyst grant

Novel PARP-1 inhibitors created at IMPACT Therapeutics

GlaxoSmithKline acquires vaccine developer Okairos

New IRAK-4 inhibitors designed by Merck & Co.

NICE issues final draft guidance recommending selective dapagliflozin use

AbbVie introduces high-dose Creon capsules in U.S.

Beijing Drug Administration accepts Sinovac's filing for EV71 vaccine candidate

Array BioPharma patents novel GPR119 receptor agonists

Encouraging topline results seen in phase II ofatumumab study

Chinese researchers report new cancer therapeutics

Idenix begins phase II study of all-oral combination of simeprevir and samatasvir for HCV

Researchers at Eli Lilly disclose novel retinoid RAR-gamma receptor antagonists

Novan reports promising findings from phase I study of acne treatment

Phase II trial to evaluate Immunovaccine's DPX-Survivac in glioblastoma

SBIR grant awarded to Orphagen for the development of novel small molecules

NEOMED and AstraZeneca expand strategic partnership

BioMarin's applications for Vimizim accepted by both FDA and EMA

FDA lifts clinical hold on phase II study of PharmAthene's anthrax vaccine

Endo Pharmaceuticals receives complete response letter from FDA regarding Aveed NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...